Active	Status	Sponsor type	Region	Phase	Filter
12 Active 10 Inactive 22 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Deng, Xiaoming
NCT05055934: Study of the Effectiveness and Safety of SHR-1314 for Psoriatic Arthritis	Completed	2	112	RoW	SHR-1314 injection, placebo	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	Psoriatic Arthritis	06/24	06/24
NCT05203705: Clinical Study on the Efficacy and Safety of Multiple Oral Administrations of SHR2285 Tablets in Patients Undergoing Elective Total Knee Arthroplasty	Recruiting	2	500	RoW	SHR2285 tablet, Enoxaparin	Shanghai Hengrui Pharmaceutical Co., Ltd.	Prevention of Venous Thrombosis After TKA	04/23	05/23
Yang, Dong Won
ALIGN, NCT04573478: Atrasentan in Patients With IgA Nephropathy	Active, not recruiting	3	404	Europe, Canada, Japan, US, RoW	Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo	Chinook Therapeutics, Inc.	IgA Nephropathy, Immunoglobulin A Nephropathy	12/26	12/26
TRAILRUNNER-ALZ 3, NCT06653153: A Study of Remternetug (LY3372993) in Early Alzheimer's Disease	Recruiting	3	1200	Europe, Canada, Japan, US, RoW	Remternetug, LY3372993, Placebo	Eli Lilly and Company	Alzheimer's Disease	04/29	10/30